A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial - EuroIntervention
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy | Business Wire
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
Comparison of Efficacy Outcomes Between Dual Antithrombotic Therapy with Dabigatran and Triple Antithrombotic Therapy with Vitamin K Antagonist Stratified by the Presence of Clinical and/or Procedural Complexity Factors in the REDUAL PCI
on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt download
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status | tctmd.com
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study | PLOS ONE
Updates in Anticoagulation: Key Sessions at ESC 2017
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire
Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? | Semantic
Subgroup Analysis from the RE-DUAL PCI Trial | tctmd.com
RE-DUAL PCI Trial: Inclusion and Main Exclusion Criteria and Study Design | Radcliffe Vascular
Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update
Switching of OAC After PCI in A-fib Patients:RE-DUAL PCI Trial Subanalysis | tctmd.com
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions
PCRonline - The RE-DUAL PCI trial subanalysis: In spite of... | Facebook
PDF) Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in
RE-DUAL OAC switching subanalysis animated video | boehringerone.com
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
Scheme of two options for antithrombotic combination therapy for... | Download Scientific Diagram
